ILIAS Biologics

Recent Finacing

Series B

Recent Raise

$20.6M

Ilias Biologics develops exosome-based therapeutics using its EXPLOR platform to load proteins into exosome lumens, advancing candidates like ILB-202 toward IND and clinical trials for inflammatory diseases and oncology.

Founded 2015

Taejon-jikhalsi, South Korea

51-100

Private

iliasbio.com

Highlights

Focus Areas

Biopharma

Biotechnology

Medical Device

Recent Investors

H

Financials

$20.6M

Total Raised

1

Funding round

10

Investors

Team

Upgrade to view the team

See the team members at ILIAS Biologics.